Analysts See $-0.41 EPS for Allena Pharmaceuticals, Inc. (ALNA)

August 9, 2018 - By Billy Entrekin

Analysts expect Allena Pharmaceuticals, Inc. (NASDAQ:ALNA) to report $-0.41 EPS on August, 14.After having $-0.38 EPS previously, Allena Pharmaceuticals, Inc.’s analysts see 7.89 % EPS growth. The stock decreased 1.71% or $0.2 during the last trading session, reaching $11.5. About 26,985 shares traded. Allena Pharmaceuticals, Inc. (NASDAQ:ALNA) has 0.00% since August 9, 2017 and is . It has underperformed by 12.57% the S&P500.

Allena Pharmaceuticals, Inc., a late-stage clinical biopharmaceutical company, engages in developing and commercializing oral enzyme therapeutics to treat patients with rare and severe metabolic, and kidney disorders in the United States. The company has market cap of $238.65 million. The company's lead product candidate includes ALLN-177, an oral enzyme therapeutic for the treatment of enteric hyperoxaluria, a metabolic disorder commonly associated with kidney stones in adults. It currently has negative earnings. It is also involved in developing ALLN-346 for patients with hyperuricemia and moderate to severe chronic kidney diseases.

More recent Allena Pharmaceuticals, Inc. (NASDAQ:ALNA) news were published by: Nasdaq.com which released: “Allena Pharmaceuticals Reports Second Quarter 2018 Financial Results and Provides Business Update” on August 07, 2018. Also Globenewswire.com published the news titled: “Allena Pharmaceuticals to Present at 2018 Wedbush PacGrow Healthcare Conference” on August 07, 2018. Seekingalpha.com‘s news article titled: “Allena Pharma’s mid-stage basket study of ALLN-177 in hyperoxaluria underway” with publication date: July 23, 2018 was also an interesting one.

Allena Pharmaceuticals, Inc. (NASDAQ:ALNA) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.